cyrilzakka/clinical-trials huggingface dataset:
Lung Aeration After Flexible Bronchoscopy in Intubated Critically Ill Patients

In patients suffering from acute respiratory failure, ineffective cough and the consequent retention of secretions are common clinical problems, which often lead to the need for tracheostomy for the sole purpose of aspiration of secretions from the airways.

Mechanically ventilated critically ill patients often have impaired mucus transport which is associated with secretion retention and subsequent development of pneumonia. The accumulation of tracheobronchial secretions in ventilated patients in ICU is due not only to an increased production, but also to a decreased clearance. In the event that secretions occlude a bronchus, an atelectasis of the lung parenchyma is created downstream. Therefore, it is often necessary to perform a flexible bronchoscopy (FOB) to proceed with the removal of the secretion plug. After its removal, the lung is supposed to be reventilated and recruited.

In intubated ICU patients, the application of a recruiting maneuver (RM) is commonly used to reopen the collapsed lung in patients with Acute Respiratory Distress Syndrome or in case of atelectasis in other clinical conditions. However, no studies have so far investigated the role of the application of a RM after a FOB performed to remove a secretion plug in intubated ICU patients.

This observational and physiological study aims to assess if the application of a RM would modify the lung aeration soon after an FOB to remove secretion plug (first outcome). Moreover, the study aims to assess if EIT could be an additional bedside imaging tool to monitor modifications of lung ventilation and aeration during and after a flexible bronchoscopy, as compared with both chest-X-ray and lung ultrasound.


Eligibility Criteria:
Inclusion Criteria:

* invasive mechanical ventilation
* need for flexible bronchoscopy to remove secretion plug from the airway

Exclusion Criteria:

* hemodynamic instability, (i.e. systolic arterial pressure \<90 mmHg or mean systolic pressure \<65 mmHg despite fluid repletion);
* need for vasoactive agents, i.e. vasopressin or epinephrine at any dosage, or norepinephrine \>0.3 mcg/kg/min or dobutamine\>5 mcg/kg/min;
* life-threatening arrhythmias or electrocardiographic signs of ischemia;
* contraindications to placement of Electrical Impedance Tomography belt, Lung UltraSound or application of a Recruiting Maneuver (i.e., pneumothorax, pulmonary emphysema, chest burns or thoracic surgery within 1 week);
* inclusion in other research protocols.
The Prospective Randomized Controlled Study of Eltrombopag on Hematopoietic Reconstruction After Allogeneic HSCT

This study evaluates the addition of Eltrombopag after Hematopoietic stem cell transplantation (HSCT) to improve the engraftment of hematopoietic stem cell. Half of the participants will receive Eltrombopag,while the other will not receive the Eltrombopag.

With the progress of transplantation technology，allogeneic hematopoietic stem cell transplantation is becoming an important treatment for hematological diseases and the long-term survival of patients is gradually improved. However, thrombocytopenia after transplantation has always been an important complication. Studies have shown that about 20% patients had different degrees of thrombocytopenia. Eltrombopag could promote hematopoietic stem cell proliferation and differentiation in vitro studies. It has also been widely used in the treatment of immune thrombocytopenia (ITP) and aplastic anemia(AA) and increased platelet levels in such diseases. Eltrombopag is also used to treat poor platelet engraftment after transplantation and the effective rate is about 60%-80%. Therefore, the application of Eltrombopag at early time after transplantation might promote platelet engraftment and reduce platelet transfusions.

Eligibility Criteria:
Inclusion Criteria:

1. Patients with definite diagnosis of hematological diseases, more than 30 kg, age18-60 years, gender and race are not limited;
2. Acceptance of allogeneic hematopoietic stem cell transplantation;
3. Voluntary acceptance of the study

Exclusion Criteria:

1. Patients with severe organ dysfunction or disease；
2. Patients who cannot tolerate oral Eltrombopag therapy;
3. Patients who refuse all-HSCT and Eltrombopag treatment;
4. Patients that investigator believed not suitable for enrollment.
Effect of Stabilization Shoes on Balance in Elderly

Movement during everyday activities most often requires stable posture. Postural control corresponds to a complex motor ability to maintain / re-establish balance and orient one's body in the environment. Postural stability and equilibrium deteriorate with age. More than 30% of people over 65 years old fall per year. Falls represent 90% of hip fractures and sometimes result in lasting psychological effects. Shoes are our direct link between the ground and our feet. Wearing shoes plays a major role in postural control. The characteristics of shoes usually worn by elderly people are identified with those of shoes known to be 'dangerous'. In order to improve stability and reduce the risk of falling for the elderly, Axis-Comfort Development® has developed "experimental balance shoes". Their shoes have technical characteristics presented in the scientific literature as beneficial for postural stability.

Therefore, the aim of this study was to investigate the effects of wearing experimental balance shoes on postural balance compared with the people's own shoes. We assumed that postural balance would be improved by experimental balance shoes in an acute way and improved by a familiarization phase.

This was a controlled, randomized, blind and cross-over study. three sessions were held in our center, each time interspersed with a phase of familiarization at home (7 to 10 days) during which the people had to wear either the experimental balance shoes or their own personal shoes. 21 volunteers in total participated in this study, all between 65 and 75 years old. Five tests were presented randomly for each session and all tests were carried out on a Huber 360 ® (LPG System, France) stabilometric platform. The mains criteria were static equilibrium on one foot and two feet (with eyes open and closed) and secondary criteria were stride frequency during the walk on the spot and stability limits.

An improvement of these multiple criteria during the different sessions would be proof of the positive effect of experimental balance shoes on postural balance in the elderly.


Eligibility Criteria:
Inclusion Criteria:

* Subjects from 65 to 75 years old
* Healthy subjects
* Having given their written informed consent

Exclusion Criteria:

* Subject who has fallen during the six months prior to the study.
* Subject who moves with walking aids.
* Subject with severe balance problems or unable to stand up without help
* Subject who takes sedatives or sleeping pills
* Subject with neurological disease (dizziness including turning dizziness, multiple sclerosis, Parkinson's, etc.)
* Subject with history of heart attack
* Subject who is short of breath when inactive.
* Subject who has pains limiting walking and standing
* Subject who takes neuroleptics except Anti-depressors if the treatment is long-standing and well-balanced.
Digital Universal Parenting Program for Positive Parenting Behaviors

The goal of this study is to evaluate use and feasibility of digitally-delivered universal parenting program, which aims to promote positive parenting among guardians with 3 years-old children.

The study will use a single-arm study design.The participants will use the universal parenting program for 8-weeks.

The intervention is a digital parent training program which focuses on positive parenting and encouraging to develop parenting skills that strengthen the relationships and communication with their children. The topics includes for example reinforcing child´s positive behavior, reducing conflict situations and planning situations advanced, managing daily transitions, and being present to child. The program includes 5 themes with recommended length of 1 week each. Each theme includes theory material, videos, examples, video practices and exercises. The program is fully digital and provided in a dynamic, web-based format. SMS and email reminders will be sent regularly during the program.

Recruitment: All parents with a 3-year old child who is participating in annual health checkup in child health clinic are considered eligible to the study and are asked to participate if they fulfil inclusion criteria and do not meet the exclusion criteria.

Eligibility Criteria:
Inclusion Criteria:

* Guardians having a child aged 3 years participating to annual health checkup in child health clinic.
* At least one of the guardians is able to understand the languages that intervention is provided in

Exclusion Criteria:

* Inability to read Finnish, Swedish, or English, as these are the languages that the intervention is provided in.
* No internet access
Prolonged Protocol of Early Follicular or Mid Luteal Phase

Due to the injection of gonadotropin releasing hormone agonist (GnRH-a) before controlled ovarian hyperstimulation (COH), the scheme of prolonged early follicular period protocol has obvious advantages in achieving ideal egg number, increasing endometrial receptivity to embryo transfer, inhibiting endogenous luteinizing hormone (LH) peak and reducing cycle cancellation rate. The full dose of long acting GnRH-a was also applied before COH in the mid luteal Hypergrowth program, and the mechanism of its lowering tone was similar. But whether the clinical and perinatal outcome of early follicular hyperlengthening is as effective as that of mid luteal hyperlengthening has not been reported at home and abroad. Moreover, there is a lack of prospective randomized controlled studies.

One injection of 3.75mg GnRHa was injected on the 1st-3rd or 21st-23rd day of menstruation. The level of estradiol (E2), progesterone (P), luteinizing hormone (LH) in peripheral blood and the number of follicles in bilateral ovarian internal sinuses were monitored on the 32nd-38th day after pituitary hyporegulation.Gonadotropin (Gn) will be given after pituitary desensitization. When the diameter of at least two follicles ≥ 18mm or more than three follicles ≥ 17mm, the trigger of human chorionic gonadotropin (hCG) will be given and oocyte will be retrieved. The selective fresh single blastocyst transplantation will be carried out on the 4th-6th day after oocyte retrieval. HCG test at 12nd day after transplatation. Follow-up investigation will given during the pregnancy and perinatal period.

Eligibility Criteria:
Inclusion Criteria:

1. Tubal factor infertility;
2. polycystic ovary (PCO) or polycystic ovary syndrome (PCOS) patients;
3. Patients of mild to moderate endometriosis；
4. Oligoasthenospermia in male；
5. More than 5 antral follicle count (AFC) on both ovaries；
6. Unexplained infertility: there is a history of no contraception and pregnancy for more than 1 year, no clear cause of infertility such as ovulation, fallopian tube, endometrium and male factors is found, or the above factors return to normal after treatment.

Exclusion Criteria:

1. History of adverse pregnancy and childbirth；
2. Unilateral ovariectomy；
3. Uterine malformation, intrauterine adhesion, submucous myoma；
4. Chromosomal abnormality of both husband and wife；
5. Patients with contraindications of assisted reproductive technology or pregnancy: such as uncontrolled diabetes mellitus, undiagnosed liver and kidney dysfunction, history of deep vein thrombosis, history of pulmonary embolism, history of cerebrovascular accident, uncontrolled hypertension, heart disease, suspected cervical cancer, endometrial cancer, breast cancer or previous history, undetermined vaginal bleeding;
6. Unable to be regularly follow up；
7. Participating in other clinical trials；
8. No fresh single blastocyst transfer.
The Prediction and Prevention of Disease by Using Big Data in Motion Analysis

Variable patterns of gait disturbance can be found in patients with spine disease including the problems of gait initiation, freezing of gait, reduced balance and postural control, reduced step lengths, increased step times, and slow walking speed.


Eligibility Criteria:
Inclusion Criteria:

* Pusan National University Hospital orthopedics, otorhinolaryngology, neurology outpatient or inpatient who agreed to the study.
* For adult men and women 18 years of age or older.

Exclusion Criteria:

* Patients unable to walk independently.
RBC Transfusion in Severe Anemia With Lactic Acidosis

The hypothesis of this study is that prolonged-storage RBCs are not inferior to short-storage RBCs for the time required to clear elevated blood lactate levels in children with severe anemia.

This study will measure the time to resolution of lactic acidosis in patients with severe anemia following blood transfusion.

Eligibility Criteria:
Inclusion Criteria:

* Age 6 mos to 5 years
* Hg \< 5 g/dL and Lactate \> 5 mM

Exclusion Criteria:

* Receiving transfusion other than RBCs
* Children with known or suspected cardiac disease
Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.

The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while maintaining an acceptable safety profile.


Eligibility Criteria:
Inclusion Criteria:

* Male or female adults aged ≥40 yrs
* Smoking history of at least 10 pack years
* Diagnosis of stable Chronic Obstructive Pulmonary Disease (COPD) as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2015)
* Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)\< 80% and ≥ 30% of the predicted normal value and post-bronchodilator FEV1/FVC (forced vital capacity) \<70%
* Modified Medical Research Council questionnaire grade of 2 or higher

Exclusion Criteria:

* Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1
* Patients with concomitant pulmonary disease
* Patients with a history of asthma
* Any patient with lung cancer or a history of lung cancer
* Patients with a history of certain cardiovascular co-morbid conditions
* Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency
* Patients in the active phase of a supervised pulmonary rehabilitation program
* Patients contraindicated for inhaled anticholinergic agents and β2 agonists
* Other protocol-defined inclusion/exclusion criteria may apply
Contingency Management for Persons With Severe Mental Illness

Contingency management is efficacious for treating cocaine abuse, but contingency management interventions have rarely been applied to patients with severe and persistent mental health problems. This pilot project will estimate effect sizes of contingency management for reducing cocaine use in patients receiving psychiatric care at a large community based mental health program. In total, 30 cocaine abusing patients will be randomized to one of two 8-week treatment conditions: standard care or standard care with contingency management. Patients in both conditions will provide breath and urine samples for toxicology testing twice per week. In the contingency management condition, patients will receive the opportunity to win prizes for submitting cocaine negative urine samples. The investigators expect that patients receiving contingency management will evidence reductions in cocaine use and may show improvements in psychiatric symptoms and psychosocial functioning relative to patients in standard care. Effect size estimates obtained from this study will be used to guide larger scale and longer duration evaluations of contingency management for dually diagnosed patients.


Eligibility Criteria:
Inclusion Criteria:

* age 18 years or older
* meet DSM-IV criteria for cocaine abuse or dependence
* English speaking
* pass a brief quiz regarding study procedures to ensure understanding of the informed consent process.

Exclusion Criteria:

* dementia
* in recovery from pathological gambling
The OPT-IN Project

Prescription opioid overdose represents a public health crisis. A number of efforts have been implemented to address opioid prescribing and opioid risk mitigation strategies for prescribers, but relatively few efforts have sought to address this problem directly with individuals who use opioids. This gap likely fails to fully address the inherent reinforcing nature of the medications that make it challenging to reduce use.

The specific aim of this study is to pilot test a toolkit that pairs an intervention with the distribution of naloxone. External facilitation (supervision check-ins) will aid translation to delivery by non-research staff. Firstly, data will be collected from participants over time as a control group, prior to training site staff. Next, non-research staff will be trained on the intervention. Staff at the site will use the online "toolkit" developed in the beginning of this project to deliver the interventions and naloxone to their clients/patients as part of usual care. After staff at the site(s) are trained, additional data will be collected from participants during the intervention period and after 3-months.

Based on feedback from non-research site staff, the OPT-IN Project implementation package was tailored for optimal delivery in the site setting. The translation strategy will be evaluated using the RE-AIM framework, which includes Reach (e.g., number of individuals receiving intervention), Effectiveness (e.g., patient/client outcomes), Adoption (e.g., numbers trained), Implementation (e.g., fidelity of intervention delivery) and Maintenance (e.g., sustained in routine practice over time) with mixed qualitative and quantitative methods with intervention recipients.

Eligibility Criteria:
Inclusion Criteria:

* Speaks English Fluently
* Receiving services at one of the investigator's partner sites
* History of opioid use

Exclusion Criteria:

* Medically unstable
* Prisoners
* Inability to speak and understand English
* Inability to give informed, voluntary, written consent for any reason
A Clinical Evaluation of PROPEL® Contour Sinus Implant

The objective of this study is to evaluate the efficacy of PROPEL Contour placement following an in-office frontal sinus balloon dilation (SBD) in patients with chronic rhinosinusitis (CRS)

A post-market, randomized, intra-patient controlled, blinded multicenter study with 80 randomized subjects at up to 20 study centers.

After successful in-office bilateral balloon dilation of the frontal sinus ostium (FSO) using the VenSure™ Nav Balloon Device and Fiagon Cube Navigation System, patients will be randomized to receive one PROPEL Contour Sinus Implant on one side while the contralateral side serves as the control.

Eligibility Criteria:
Inclusion Criteria:

1. Patient is 18 years of age or older.
2. Patient is willing and able to comply with protocol requirements.
3. Patient has confirmed diagnosis of CRS per International Consensus Statement on Allergy and Rhinology, Rhinosinusitis 2021 (ICAR:RS) guidelines.
4. Bilateral disease in the frontal sinuses (Lund-Mackay CT score of ≥1 on each side) on CT scan within 90 days prior to the baseline.
5. A successfully completed in-office bilateral balloon dilation of the FSO with no complication on either side that, in the opinion of the clinical investigator is amenable for PROPEL Contour Sinus Implant placement in both FSO

Exclusion Criteria:

1. Patient has structural obstruction that precludes endoscopic visualization of one or both FSOs prior to implant placement.
2. Expanded amount of ethmoid sinonasal polyps extending beyond the middle meatus (grade \> 2) unless reduced 30 days prior to the baseline procedure
3. Oral-steroid dependent condition such as chronic obstructive pulmonary disease (COPD) or other conditions.
4. Known history of allergy or intolerance to corticosteroids or mometasone furoate.
5. Patients with a known hypersensitivity to lactide, glycolide or caprolactone copolymers.
6. Patients with electronic devices in direct connection to the brain or the nervous system such as implantable neurostimulators (e.g. deep brain stimulation), programmable cerebrospinal fluid (CSF) shunts.
7. Patients with monopolar pacemakers (older designs, with lower resistance to interference) or ICD's (implantable cardioverter defibrillator).
8. Patients with implantable, body worn devices such as insulin pumps.
9. Evidence of purulence coming from paranasal sinuses or ostiomeatal complex.
10. Clinical evidence of acute bacterial sinusitis or invasive fungal sinusitis (e.g. bone erosion on prior CT scan, necrotic sinus tissue).
11. Active viral illness (e.g., flu, shingles).
12. Use of parenteral or injected steroids (e.g. Kenalog) 30 days prior to the baseline procedure.
13. Use of oral steroids, budesonide or other sinus steroid irrigations/rinses or drops, nebulized steroids administered nasally 14 days prior to baseline procedure.
Continuous Versus Repetitive Sevoflurane Administration for Preconditioning

Pharmacologic preconditioning by volatile anesthetics may depend on the mode of administration. The researchers hypothesize that a continuous administration in patients scheduled for CABG surgery prebypass will be less effective in terms of attenuating myocardial cell damage compared to a repetitive administration with a double wash in/wash out schedule. A control group will receive propofol as their primary anesthetic.


Eligibility Criteria:
Inclusion Criteria:

* Patients schedulded to undergo CABG surgery
* Age 18 to 80 years
* Ejection fraction \> 40%

Exclusion Criteria:

* Emergency cases
* Diabetes
* Not able to give informed consent
* Ejection fraction \< 40%
Comparing Effects of Whole Body Vibration and Resisted Training on Quadriceps Strength After Lower Limb Burns

Evaluate the therapeutic effect of Whole body vibration and Resistance training on strength of quadriceps post lower limb burn

Study Design:

This randomized controlled trial will include 60 patients suffering from partial thickness burns. The patients will be randomly divided into two equal groups, with each group consisting of 30 patients.

Study Explanation:

A verbal explanation about the importance of the study, its procedures, main aims, and conceptual approach will be provided to every patient.

Study Procedures:

The procedures of this study will be divided into two main categories: evaluation procedures and treatment procedures.

Evaluation Procedures:

Evaluation will be conducted using isokinetic dynamometry for all patients both before and after the study.

Treatment Procedures:

First Group: Patients in the first group will receive whole body vibration therapy.

Second Group: Patients in the second group will undergo resisted exercises.

Eligibility Criteria:
Inclusion Criteria:

The subject selection will be according to the following criteria:

* Age range between 25-40 years.
* Male and female patients will participate in the study.
* All patients have burn of 30% to 40%.
* All patients have burn at lower limb
* All patients have second degree burn
* All patients have no chronic diseases.
* All patients enrolled to the study will have their informed consent

Exclusion Criteria:

The potential participants will be excluded if they meet one of the following criteria:

* Prosthesis;
* Any neurological, musculoskeletal,or other chronic disease
* Participation in an outside resistance training programs
* Recent fracture or bone injury
* Any medication that could affect strength adaptations and adversely affect the results of the study
* Previous brain injury
* Any disease affecting balance, vestibular or visual disorders
* History of epilepsy.
* Cardiac diseases.
* Burn of sole of foot.
* Exposed foot tendons.
* Severe osteopathy.
* Marked anemia (Ht\<25%).
* Serious peripheral vessel disease
* Acute medical problem at study onset.